person working in a lab

Genomics Birmingham

person working in a lab

Genomics Birmingham provides expert genomic, transcriptomic, epigenetic and some proteomic based services, along with a Technology Suite for researcher access. Our specialist team pursue excellence, while incorporating the latest technological developments.

Genomics Birmingham comprises a specialist team using the latest genomic technologies to support genomic, transcriptomic and epigenetic based research. The service was founded in 2016 and is housed over three purpose-built laboratories, in a fully equipped facility, largely funded through University of Birmingham and the MRC. We provide a trusted service supporting experimental design, as well as sample processing. Projects are focused towards University of Birmingham researchers, but we welcome collaboration with external academics and commercial businesses.

Genomics Birmingham Team

Claire Bryer

Genomics Specialist

Claire Bryer, BSc (Hons)

Claire studied Biological Sciences (Genetics) at University of Birmingham, graduating in 2010. Her first position was working in the Department of Biochemistry (University of Oxford) as a technician, learning fundamental molecular biology techniques using S. pombe. She then moved on to the Genomics core facility (OGC) at Oxford University (2014-2017). This provided a solid foundation for her next role as a CRUK-funded Genomics Scientist within Genomics Birmingham at UoB (2017-2021). Claire then expanded her skills within an industrial setting, working as a Senior Automation Scientist at Nonacus Ltd (2021-2024), and implemented a COVID-19 sequencing service. She has become a genomic assay development and automation specialist with expertise in: RNAseq, WGS, WES, amplicon, single-cell, and ATAC-seq. Claire brings her substantial technical skill and accumulated knowledge back to Genomics Birmingham, UoB (from Dec 2024) with a focus on single-cell technology.

 

Kate Carruthers

Genomics Specialist

Kate Carruthers, MBiomed

Kate studied Biomedical Science at Cardiff University and was awarded an integrated masters degree in 2019. Her masters project focussed on investigating the effects of external influences on gene expression in the development of osteoarthritis. Kate then worked in the West Midlands Regional Genetics Laboratories, processing clinical samples for genetic analysis by performing next generation sequencing techniques. Kate joined the Genomics Birmingham team in 2023 to use and expand her skills in NGS technologies.

Kamila Orzechowska

 

Senior Research Technician

Kamila Orzechowska, BSc (Hons), MSc

Kamila has a BSc in Biological and Chemical Sciences in 2021 from Coventry University and an MSc in Molecular Biotechnology in 2022 from University of Birmingham. She was awarded “The Olly Beswetherick Prize in Molecular Biotechnology” for the best research project during her MSc. While working at ALS Environmental she gained experience in water samples microbial analysis. She joined the Beggs Group in February 2023 and recently she has joined the Genomics Birmingham Team. 

 

 Ross Worledge

Senior Research Technician

Ross Worledge, BSc (Hons), MRes

Ross studied Biomedical Science at Aston University. This included NIHR placements in 2020/21, based at Wolverhampton University, researching Crohn’s disease and IBD and at the Wellcome Trust Birmingham Clinical Research Facility working predominantly on processing samples for COVID-19 vaccine trials. Ross also obtained a MRes at Aston, where he researched the effect of vesicles on the immune system and the regulation of inflammation. He joined the Genomics Birmingham team to expand his skillset and ability.

 

Senior Research Technician

Mahema Khan, BSc (Hons)

Mahema studied a Bachelor of Science in Biochemistry at University of Birmingham. Following graduation, she undertook a research placement at the Babraham Institute where she explored the expression of non-canonically imprinted genes in mice. She worked as a research assistant at the Wellcome Sanger Institute supporting research in somatic genomics and cancer. During her time at Sanger, she completed a visiting placement at the Milner Therapeutics Institute where she gained experience in pooled CRISPR screening and spatial biology techniques. Mahema joined Genomics Birmingham in 2026 to expand her skillset in genomic technologies.

 

Senior Research Technician

Jessica Neil, BSc (Hons), MSc

Jessica completed BSc (Hons) in Biological Sciences (Genetics), followed by an MSc in Genomic Medicine in 2025, at the University of Birmingham. Her MSc research project was published in Bladder Cancer, where she focused on developing an extended version of the GALEAS bladder gene panel to detect FGFR3 fusions in bladder cancer patients. Following her studies, she worked in a Containment Level 3 laboratory, developing a qPCR-assay for the detection of Shiga toxin-producing E. coli in food and water samples. Jessica has since joined the Genomics Birmingham team to further expand her genomics knowledge.

 

Samantha Tull

Facility Manager

Dr Samantha Tull

Dr Samantha Tull is the facility manager of the newly expanded Genomic Birmingham (October 2023). She obtained a BSc (Hons) in Bioanalytical Sciences, an MSc in Experimental and Molecular Pathology and a PhD in Cardiovascular Sciences. During her time at UoB, she obtained PCAP (associated fellow) qualification. Her research was based at the University of Leicester, then here at UoB and at Viatem Ltd (a UoB spin out company). Samantha has published first, last and middle author research papers in the fields of cardiovascular, IBD and renal inflammatory disease. The team will continue to bring genomic research to life for their clients/users.

 

Andrew Beggs

Genomics Birmingham Academic Lead

Professor Andrew Beggs

Training and Support

Visit the Genomics Birmingham User Registration Page.

Genomics Birmingham provides training for the Applied biosystems Qs5 384 and 96-well RT-PCR systems and Cellrad irradiator, this can be requested via Stratocore. Currently, our training programmes are divided into two sections. Firstly, the canvas module which can be completed at the user’s pace and once that is completed we deliver an in person training session at the equipment.

We deliver sessions regularly. For our bespoke services, please reach out to us to discuss your project and how we can help you.

Equipment Access

External users are encouraged to contact us via email in the first instance, however, all internal prospective users will need to request an account on the core facilities booking system Stratocore (unless you already have one). Please ensure you use your UoB email address to register your Stratocore account.

As part of your account, you will need a valid finance/grant code. We need this to be able to charge you for your use of the equipment. Your code will either be a project or a general ledger. Guidance on finance/grant codes is here:

Project Ledger

(Project Finance Number begins with a ‘1’ or ‘2’). Project Ledger codes require 3 components in the format:

Project Ledger Code Components

Cost Centre Code Task Number Project Finance Number
C082 1.1 21991

General Ledger. (Project Finance Number begins with a ‘6’). General Ledgers require 2 components in the format:

General Ledger Code Components

Cost Centre Code Project Finance Number
C283

65371

Visit the Genomics Birmingham User Registration Page.

Genomic services

  • DNA/RNA quantification and fragment length assessment using the Qubit Fluorometer and Tapestation
  • Next generation sequencing on Illumina MiSeq, NextSeq 2000 and NovaSeq 6000
  • Library prep and next generation sequencing on the Ion Torrent Genexus Integrated Sequencer
  • NGS library preparation covering a wide range of RNAseq/DNAseq applications including low input and FFPE samples
  • Single cell technologies including 3’/5' transcript profiling, V(D)J, ATAC, fixed cell, multiome and spatial transcriptomics
  • Oxford Nanopore sequencing using the PromethION platform for long read RNA/DNA sequencing and methylation detection
  • Project planning and writing grant application quotes
  • Sample processing advice

Olink Proteomic services

Olink Proteomic Services Genomics Birmingham provides end-to-end Olink proteomic services across the Target 48, Target 96, Reveal and Explore HT platforms. These assays utilise Olink's Proximity Extension Assay (PEA) technology to enable highly sensitive and specific multiplex protein analysis from minimal sample volumes. Applications range from targeted biomarker validation to large-scale discovery proteomics. Services are available for a range of sample types including serum, plasma, saliva, tissue culture supernatants and synovial fluid.

  • Target 48 and Target 96 proteomic analyses using the Signature Q100 microfluidic qPCR system. Service launched in early 2024.
  • Reveal measures approximately 1,000 proteins in up to 86 samples. Libraries are sequenced on the Illumina NextSeq 2000 platform. Service launched in autumn 2025.
  • Explore HT measures approximately 5,400 proteins in up to 172 samples. Sample preparation is supported by Dragonfly, FAST and Hamilton STARlet robotic platforms, with sequencing performed on the Illumina NovaSeq platform. Service launched in spring 2026.

Acknowledgement Statement

The University of Birmingham (UoB) is a founding signatory of ‘The Technician Commitment’. A sector-wide, collaborative initiative that aims to ensure visibility, recognition, career development and sustainability for technical staff working in higher education and research, across all disciplines.

The UoB has invested in and supports the Technology Hub facilities not only with equipment but also with specialist staff. The staff are a key element of our offering, as they ensure that all equipment is looked after and performing to specification. Their significant experience and valuable input and advice are also beneficial to our users.

In line with this, the Technology Hub Facilities request that all users of the facilities recognise its contribution to manuscripts in one of the following ways:

The authors would like to acknowledge the (Facility) at the UoB for support of (technology used) experiments. The authors would like to acknowledge (specialist name).

In some instances, the specialist may make substantial contributions to the conception / design of the work or the acquisition, analysis, or interpretation of data for a manuscript. In this case, it is expected that this is appropriately recognised through co-authorship on any publications resulting from the work. Criteria for inclusion of a specialist as an author on a publication. Where the specialist has either:

  • Performed experiments or analysis, the data from which is included in the manuscript.
  • Produced customised analysis workflows or scripts for the work.
  • Significantly contributed to the design, conception, or interpretation of the experiments.

Publications

Yiangou, A., Do, T.P., Grech, O. et al. CGRP-provoked headache is associated with a neuroimmune signature in idiopathic intracranial hypertension. J Headache Pain 27, 159 (2026). https://doi.org/10.1186/s10194-026-02385-0

Yevlashevskaya, O., Davies, J.Z., Choi, J. et al. An organotypic oral squamous cell carcinoma model recapitulates epithelial-stromal complexity at single-cell resolution and reveals matrix-derived signalling as a therapeutic target. bioRxiv (2026). https://doi.org/10.64898/2026.03.10.7107693.

Davies, N., Francis, T., Oldreive, C. et al. Genome-scale clustered regularly interspaced short palindromic repeats screen identifies nucleotide metabolism as an actionable therapeutic vulnerability in diffuse large B-cell lymphoma. Haematologica 109(12), 3989–4006 (2024). https://doi.org/10.3324/haematol.2023.2844044.

Conway, J., De Jong, E.N., White, A.J. et al. Age-related loss of intestinal barrier integrity plays an integral role in thymic involution and T cell ageing. Aging Cell 24(3), e14401 (2025). https://doi.org/10.1111/acel.14401

Potluri, S., Kellaway, S.G., Coleman, D.J.L. et al. Gene regulation in t(6;9) DEK::NUP214 acute myeloid leukemia resembles that of FLT3-ITD/NPM1 acute myeloid leukemia but with an altered HOX/MEIS axis. Leukemia 38, 403–407 (2024). https://doi.org/10.1038/s41375-023-02118-1

Coleman, D.J.L., Keane, P., Luque-Martin, R. et al. Gene regulatory network analysis predicts cooperating transcription factor regulons required for FLT3-ITD+ AML growth. Cell Rep 42(12), 113568 (2023). https://doi.org/10.1016/j.celrep.2023.113568

Mahony, C.B., Copper, L., Vrljicak, P. et al. Lineage skewing and genome instability underlie marrow failure in a zebrafish model of GATA2 deficiency. Cell Rep 42(6), 112571 (2023). https://doi.org/10.1016/j.celrep.2023.1125718.

Wijesinghe, S.N., Badoume, A., Nanus, D.E. et al. Obesity-defined molecular endotypes in the synovium of patients with osteoarthritis provides a rationale for therapeutic targeting of fibroblast subsets. Clin Transl Med 13(4), e1232 (2023). https://doi.org/10.1002/ctm2.1232

Hadzhiev, Y., Wheatley, L., Cooper, L. et al. The miR-430 locus with extreme promoter density forms a transcription body during the minor wave of zygotic genome activation. Dev Cell 58(2), 155–170.e8 (2023). https://doi.org/10.1016/j.devcel.2022.12.007

Edginton-White, B., Maytum, A., Kellaway, S.G. et al. A genome-wide relay of signalling-responsive enhancers drives hematopoietic specification. Nat Commun 14(1), 267 (2023). https://doi.org/10.1038/s41467-023-35910-9

Adamo, A., Chin, P., Keane, P. et al. Identification and interrogation of the gene regulatory network of CEBPA-double mutant acute myeloid leukemia. Leukemia 37(1), 102–112 (2023). https://doi.org/10.1038/s41375-022-01744-5

Baranasic, D., Hörtenhuber, M., Balwierz, P.J. et al. Multiomic atlas with functional stratification and developmental dynamics of zebrafish cis-regulatory elements. Nat Genet 54(7), 1037–1050 (2022). https://doi.org/10.1038/s41588-022-01089-w

Bevington, S.L., Fiancette, R., Gajdasik, D.W. et al. Stable epigenetic programming of effector and central memory CD4 T cells occurs within 7 days of antigen exposure in vivo. Front Immunol 12, 642807 (2021). https://doi.org/10.3389/fimmu.2021.642807

Potluri, S., Assi, S.A., Chin, P.S. et al. Isoform-specific and signaling-dependent propagation of acute myeloid leukemia by Wilms tumor 1. Cell Rep 35(3), 109010 (2021). https://doi.org/10.1016/j.celrep.2021.109010

Wang, J., Rojas, P., Mao, J. et al. Persistence of RNA transcription during DNA replication delays duplication of transcription start sites until G2/M. Cell Rep 34(7), 108759 (2021). https://doi.org/10.1016/j.celrep.2021.108759

Kellaway, S.G., Keane, P., Edginton-White, B. et al. Different mutant RUNX1 oncoproteins program alternate haematopoietic differentiation trajectories. Life Sci Alliance 4(2), e202000864 (2021). https://doi.org/10.26508/lsa.202000864

Chin, P.S., Assi, S.A., Ptasinska, A. et al. RUNX1/ETO and mutant KIT both contribute to programming the transcriptional and chromatin landscape in t(8;21) acute myeloid leukemia. Exp Hematol 92, 62–74 (2020). https://doi.org/10.1016/j.exphem.2020.10.005

Contact Us

All general enquiries to Genomics Birmingham should be directed to:

Telephone: +44 (0)121 415 8139
Email: cmh-sequencing@contacts.bham.ac.uk

Facility Manager

Dr Samantha Tull

Email: s.p.tull@bham.ac.uk

Genomics Birmingham Academic Lead

Professor Andrew Beggs

Email: a.beggs@bham.ac.uk

Social media

Follow the Genomics Birmingham UOB LinkedIn page

 

Testimonials

Dr Juma el-Awaisi

Birmingham Springboard and Asthma + Lung UK Fellow

Department of Cardiovascular Sciences

The Genomics Birmingham team have been extremely helpful from the very beginning. My own background is not in genomics, so the team really supported me throughout the process, from our initial discussions about the best technology to use to answer my scientific questions, through to planning and optimising the experimental approach.

They were a massive help in optimising and selecting the most appropriate protocol for fixation and cell isolation. I tried a few different methods, and the team worked with me to test cell counts and viability before deciding on the best approach. From there, we agreed to trial one of the new systems they had available. The team arranged for the company to come in and support during the trial and then provided the data for my own analysis.

Through their events and wider network, they also introduced me to technology providers who helped point me towards different options for downstream analysis. This support has been invaluable in helping me move the project forward.

Special thanks to Samantha Tull, Claire Bryer, Kate Carruthers, and the wider Genomics Birmingham team for all their support.

Dr Mansimran Singh Dulay MBBS BSc (Hons) MRCP

Royal Brompton and Harefield Hospitals, KCL, London

Genomics Birmingham were superb from start to finish and I couldn’t recommend them enough.

I am a first-time proteomics user currently conducting my PhD and chose Genomics Birmingham to analyse my plasma sample using target 96 Cardiovascular II.

Their advice, support, communication and help throughout was second-to-none. The turnaround to results was very fast, with clearly presented data as promised.

A special thanks to Kate who provided so much help throughout the run-up to analysis, including rapidly responding to all of my many queries.

I wouldn’t hesitate to use Genomics Birmingham again and have indeed recommended them to all of my colleagues.

https://doi.org/10.1016/j.hlc.2026.03.064

Dr Michael Sagmeister

Clinical Lecturer in Renal Medicine

University of Birmingham 

Working with the Genomics Birmingham team has been an excellent experience. Their expertise in Olink technology and responsiveness to queries provided invaluable support throughout the planning and execution of my project. The team offered clear guidance on assay selection and workflows, making the sample submission process straightforward and efficient.

Genomics Birmingham performed the Olink Target 48 cytokine panel on my samples, delivering outstanding assay performance—with absolute quantifications for 90% of datapoints in conditioned media and over 99% in human serum. The resulting dataset was rich and high-quality, providing a robust platform to test key hypotheses and explore new research directions. I would strongly recommend the Genomics Birmingham facility to colleagues seeking expert, reliable support for Olink proteomic studies.

Jia Dai Mi (PhD student)

King’s College London, based at St Thomas’ Hospital, London. 

We are very pleased with the Olink services provided by the Birmingham Genomics team on our preterm birth research project here at King’s College London. The team has been consistently helpful and responsive throughout the project, and data generated on the Olink platform has delivered valuable insights that are actively shaping the direction of our research. We look forward to working with them again in future projects.

Single Cell Sequencing
10x Genomics Chromium X in the lab

10x Genomics Chromium X

Proteomics
Olink Signature Q100 in the lab

Olink Signature Q100